-
CHOOSING FOR THE WORSE-OFF: A STRUCTURAL SOCIAL WELFARE MODEL OF EQUITY-EFFICIENCY PREFERENCES IN TYPE 2 DIABETES TREATMENT CHOICES
Mar 18, 2026, 21:38 PM -
VALIDATION OF AN AGENTIC LARGE LANGUAGE MODEL (LLM) SYSTEM IN THE REVIEW STAGE OF A REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR): A SOLUTION TO INSTANT AND EASY ACCESS TO CLINICAL TRIAL DATA (CTD)
Mar 18, 2026, 21:38 PM -
SURVEY OF ATTITUDES TOWARDS HPV VACCINATION AMONG YOUNG PEOPLE
Mar 18, 2026, 21:38 PM -
ENSURING ESTIMAND AND POPULATION CONSISTENCY ACROSS HEALTH TECHNOLOGY ASSESSMENT DOSSIER COMPONENTS
Mar 18, 2026, 21:38 PM -
COMPREHENSIVE REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) OUTPERFORM CUSTOM REVIEWS FOR STRATEGIC HEALTH TECHNOLOGY ASSESSMENT (HTA) AND MARKET ACCESS (MA) PLANNING: AN ADVANCED METASTATIC BREAST CANCER (MBC) EXAMPLE
Mar 18, 2026, 21:38 PM -
EVALUATING INDIVIDUAL-LEVEL ASSOCIATION BETWEEN RADIOGRAPHIC PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN METASTATIC-HORMONE SENSITIVE PROSTATE CANCER (MHSPC): AN INDIRECT ILLNESS-DEATH MODELING APPROACH
Mar 18, 2026, 21:38 PM -
CLINICAL AND ECONOMIC BENEFITS OF EARLY ROMOSOZUMAB INITIATION IN PATIENTS WITH RECENT OSTEOPOROTIC HIP FRACTURES IN JAPAN
Mar 18, 2026, 21:38 PM -
THE IMPACT OF DIFFERENT TIME-VARYING NETWORK META-ANALYSIS METHODS TO ASSESS TALAZOPARIB + ENZALUTAMIDE VERSUS OLAPARIB + ABIRATERONE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT AND COST CALCULATOR MODEL FOR POHERDY® (PERTUZUMAB-DPZB) IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER
Mar 18, 2026, 21:38 PM -
A COMPARATOR CHOICE SET FRAMEWORK FOR VALUE-BASED PRICING UNDER THE INFLATION REDUCTION ACT
Mar 18, 2026, 21:38 PM -
INNOVATIVE GRAPH BASED CLUSTERING TO IDENTIFY SJÖGREN’S DISEASE SUBTYPES FROM REAL-WORLD DIAGNOSTIC JOURNEYS
Mar 18, 2026, 21:38 PM -
COST EFFECTIVENESS OF EARLY VS DELAYED AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA
Mar 18, 2026, 21:38 PM -
ASSESSING THE UTILIZATION OF EARLY ACCESS PATHWAYS AND IMPLEMENTATION OF TIME-LIMITED REIMBURSEMENT AND TEMPORARY ACCESS PROCESS IN CANADA
Mar 18, 2026, 21:38 PM -
REAL-WORLD COMPARATIVE EFFECTIVENESS OF LUTETIUM-177-PSMA-617 VERSUS CABAZITAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS IN MEN WITH PROSTATE CANCER TREATED WITH ANDROGEN DEPRIVATION THERAPY USING REAL-WORLD DATA
Mar 18, 2026, 21:38 PM -
DOES VULNERABILITY DRIVE UTILIZATION: ASSESSING DIFFERENTIAL HEALTHCARE UTILIZATION AMONG DUAL-ELIGIBLE VERSUS FEE-FOR-SERVICE MEDICARE BENEFICIARIES FROM EARLY TO MID-STAGE AD/ADRD/MCI
Mar 18, 2026, 21:38 PM -
A NOVEL MULTIVARIATE APPLICATION OF PROFILE ANALYSIS TO CHARACTERIZE MULTIDOMAIN PATIENT-REPORTED OUTCOME (PRO) PATTERNS IN PATIENTS WITH GASTRIC OR GASTROESOPHAGEAL JUNCTION (GC/GEJC) ADENOCARCINOMA
Mar 18, 2026, 21:38 PM -
VALIDATION OF A CLAIMS ALGORITHM TO IDENTIFY PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1 (DM1)
Mar 18, 2026, 21:38 PM -
FIRST-YEAR COST PER RESPONDER FOR BRODALUMAB COMPARED WITH OTHER BIOLOGIC THERAPIES FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN CANADA
Mar 18, 2026, 21:38 PM -
A FRAMEWORK FOR INTEGRATING THE ESTIMANDS INTO FEASIBILITY OF NETWORK META-ANALYSES OF RANDOMIZED CONTROLLED TRIALS
Mar 18, 2026, 21:38 PM
